var data={"title":"Darbepoetin alfa: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Darbepoetin alfa: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5980?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=darbepoetin-alfa-drug-information\" class=\"drug drug_general\">see &quot;Darbepoetin alfa: Drug information&quot;</a> and <a href=\"topic.htm?path=darbepoetin-alfa-patient-drug-information\" class=\"drug drug_patient\">see &quot;Darbepoetin alfa: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50080059\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Aranesp Canadian Safety Alert</span>\n      <span class=\"collapsible-date\">May 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Health Canada has announced that severe and life-threatening skin reactions, including Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), have been reported in patients treated with darbepoetin alfa (Aranesp). Health care providers are advised to discontinue darbepoetin alfa immediately if a severe skin reaction occurs or SJS/TEN is suspected and to permanently discontinue darbepoetin alfa if SJS/TEN is confirmed. Health Canada is currently working with the manufacturer to include this safety information in the Canadian Product Monograph.</p>\n        <p style=\"text-indent:0em;\">For further information visit http://healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2017/63198a-eng.php.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708695\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cardiovascular events:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Erythropoiesis-stimulating agents (ESAs) increase the risk of death, myocardial infarction (MI), stroke, venous thromboembolism, thrombosis of vascular access.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Chronic kidney disease:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered ESAs to target a hemoglobin level of more than 11 g/dL.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">No trial has identified a hemoglobin target level, darbepoetin alfa dose, or dosing strategy that does not increase these risks.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Use the lowest darbepoetin alfa dose sufficient to reduce the need for red blood cell (RBC) transfusions.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cancer:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid RBC transfusion.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Use ESAs only for treatment of anemia from myelosuppressive chemotherapy.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Discontinue following the completion of a chemotherapy course.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156983\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Aranesp (Albumin Free)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156984\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Aranesp</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057681\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Colony-Stimulating Factor</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Erythropoiesis Stimulating Protein</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Hematopoietic Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057675\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=darbepoetin-alfa-drug-information\" class=\"drug drug_general\">see &quot;Darbepoetin alfa: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> Dosing schedules need to be individualized and careful monitoring of patients receiving the drug is recommended. Use has not been demonstrated in controlled clinical trials to improve symptoms of anemia, quality of life, fatigue, or patient well-being.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anemia associated with chronic kidney disease (CKD) (<span style=\"text-decoration: underline\">ON</span> dialysis): Note:</b> IV route is preferred for hemodialysis patients; initiate treatment when hemoglobin is &lt;10 g/dL; reduce dose or interrupt treatment if hemoglobin approaches or exceeds 12 g/dL (if &lt;18 years of age) or 11 g/dL (if &ge;18 years of age):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i> Initial</i>: IV (preferred), SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents &lt;18 years: 0.45 mcg/kg once weekly</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &ge;18 years: 0.45 mcg/kg once weekly <b>or</b> 0.75 mcg/kg once every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosage adjustment:</i> Children and Adolescents: IV (preferred), SubQ: Do not increase dose more frequently than every 4 weeks (dose decreases may occur more frequently).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If hemoglobin increases &gt;1 g/dL in any 2-week period: Decrease dose by &ge;25%</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If hemoglobin does <b>not</b> increase by &gt;1 g/dL after 4 weeks: Increase dose by 25%</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Inadequate or lack of response: If adequate response is not achieved over 12 weeks, further increases are unlikely to be of benefit and may increase the risk for adverse events; use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid red blood cell transfusions <b>and</b> evaluate patient for other causes of anemia; discontinue treatment if responsiveness does not improve.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Anemia associated with chronic kidney disease (CKD) <span style=\"text-decoration: underline\">(NO</span> dialysis): Note:</b> Initiate treatment when hemoglobin is &lt;10 g/dL; use only if rate of hemoglobin decline would likely result in RBC transfusion and desire is to reduce risk of alloimmunization or other RBC transfusion-related risks; reduce dose or interrupt treatment if hemoglobin exceeds 12 g/dL (if age &lt;18 years) or 10 g/dL (if age &ge;18 years):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Initial:</i> IV, SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents &lt;18 years: 0.45 mcg/kg once weekly <b>or </b>0.75 mcg/kg once every 2 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents &ge;18 years: 0.45 mcg/kg once every 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Dosage adjustment:</i> Children and Adolescents: IV, SubQ: Do not increase dose more frequently than every 4 weeks (dose decreases may occur more frequently).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If hemoglobin increases &gt;1 g/dL in any 2-week period: Decrease dose by &ge;25%</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">If hemoglobin does not increase by &gt;1 g/dL after 4 weeks: Increase dose by 25%</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Inadequate or lack of response: If adequate response is not achieved over 12 weeks, further increases are unlikely to be of benefit and may increase the risk for adverse events; use the minimum effective dose that will maintain a hemoglobin level sufficient to avoid red blood cell transfusions <b>and</b> evaluate patient for other causes of anemia; discontinue treatment if responsiveness does not improve</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Conversion from epoetin alfa to darbepoetin alfa: </b>Children and Adolescents: Determination of weekly darbepoetin dose is based on the weekly epoetin dose at time of conversion; see the following table.</p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption>\n        <b>Conversion From Epoetin Alfa to Darbepoetin Alfa (IV or SubQ) (maintain the same route of administration for the conversion)</b></caption>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <col align=\"center\"></col>\n      <thead>\n        <tr>\n          <th rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Previous Weekly Epoetin Alfa Dose </b></p>\n            <p style=\"text-indent:0em;\">\n              <b>(units/week)</b></p></th>\n          <th colspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Weekly Darbepoetin Alfa Dosage</b></p></th></tr>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b> Age 1 to &lt;18 years</b></p>\n            <p style=\"text-indent:0em;\">\n              <b>(mcg/week)</b></p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">\n              <b>Age </b>\n              <b>&ge;</b>\n              <b>18 years</b></p>\n            <p style=\"text-indent:0em;\">\n              <b>(mcg/week)</b></p></th></tr></thead>\n      <tfoot>\n        <tr>\n          <td colspan=\"3\" align=\"left\">\n            <p style=\"text-indent:0em;\">\n              <b>Note</b>: Due to the longer serum half-life of darbepoetin alfa, when converting from epoetin alfa, administer darbepoetin alfa once weekly if the patient was receiving epoetin alfa 2 to 3 times weekly and administer darbepoetin alfa once every 2 weeks if the patient was receiving epoetin alfa once weekly.</p></td></tr></tfoot>\n      <tbody>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;1,500</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Not established</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6.25</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">1,500 to 2,499</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6.25</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">6.25</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">2,500 to 4,999</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">10</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">12.5</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">5,000 to 10,999</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">11,000 to 17,999</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">40</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">40</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">18,000 to 33,999</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">60</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">60</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">34,000 to 89,999</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">100</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;90,000</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">200</p></td></tr></tbody></table>\n    </div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156961\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aranesp (Albumin Free): 25 mcg/mL (1 mL); 40 mcg/mL (1 mL); 60 mcg/mL (1 mL); 100 mcg/mL (1 mL); 150 mcg/0.75 mL (0.75 mL [DSC]); 200 mcg/mL (1 mL); 300 mcg/mL (1 mL) [albumin free; contains mouse (murine) and/or hamster protein, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Injection [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aranesp (Albumin Free): 10 mcg/0.4 mL (0.4 mL); 25 mcg/0.42 mL (0.42 mL); 40 mcg/0.4 mL (0.4 mL); 60 mcg/0.3 mL (0.3 mL); 100 mcg/0.5 mL (0.5 mL); 150 mcg/0.3 mL (0.3 mL); 200 mcg/0.4 mL (0.4 mL); 300 mcg/0.6 mL (0.6 mL); 500 mcg/mL (1 mL) [albumin free; contains mouse (murine) and/or hamster protein, polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156947\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874543\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103951s5375lbl.pdf#page=25&amp;token=vGWlCfEYW79EZLSeG8kYJH9emtrpASSVXWLbMiNXfo79r0J0U2n6A065FPtnfhoz4rmC2rRPTEdlc+muEMobILp69bgIa57F8XwDf5nZXnXwtTMLPNb/fGuF92ocNSr0&amp;TOPIC_ID=13206\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/103951s5375lbl.pdf#page=25</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057684\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">May be administered undiluted IV or SubQ. IV route preferred for hemodialysis patients. Do not shake as this may denature the glycoprotein rendering the drug biologically inactive. Do not administer in conjunction with other drug solutions. Discard any unused portion of the vial; do not pool unused portions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156979\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. Do not shake. Protect from light. Store in original carton until use. The following stability information has also been reported: May be stored at room temperature for up to 7 days (Cohen 2007). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057683\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of anemia due to chronic kidney disease (FDA approved in ages &ge;1 year and adults); treatment of anemia associated with concurrent myelosuppressive chemotherapy for nonmyeloid malignancies receiving chemotherapy (palliative intent) for a planned minimum of 2 additional months of chemotherapy (FDA approved in adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2136826\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Aranesp may be confused with Aralast, Aricept</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Darbepoetin alfa may be confused with dalteparin, epoetin alfa, methoxy polyethylene glycol-epoetin beta</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F157016\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris, edema, hypotension, myocardial infarction, hypertension, peripheral edema, pulmonary embolism, thromboembolism, thrombosis of hemodialysis vascular access, thrombosis of vascular graft (arteriovenous)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Cerebrovascular disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Erythema, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypervolemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, dyspnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, anemia (associated with neutralizing antibodies; severe; with or without other cytopenias), angioedema, bronchospasm, cerebrovascular accident, hypersensitivity reaction, hypertensive encephalopathy, pure red cell aplasia, seizure, tumor growth (progression/recurrence; cancer patients), urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156966\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serious allergic reaction to darbepoetin alfa or any component of the formulation; uncontrolled hypertension; pure red cell aplasia (PRCA) that begins after treatment with darbepoetin alfa or other erythropoietin protein drugs</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in the US labeling): Sensitivity to mammalian cell-derived products</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156951\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events: <b>[US Boxed Warning]: Erythropoiesis-stimulating agents (ESAs) increased the risk of serious cardiovascular events, myocardial infarction, stroke, venous thromboembolism, vascular access thrombosis, and mortality in clinical studies when administered to target hemoglobin levels &gt;11 g/dL</b> (and provide no additional benefit); a rapid rise in hemoglobin (&gt;1 g/dL over 2 weeks) may also contribute to these risks.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cutaneous reactions: Erythema multiforme and Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN) have been reported with ESA use; discontinue immediately if a severe cutaneous reaction develops.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Potentially serious allergic reactions have been reported (rarely), including anaphylactic reactions, angioedema, bronchospasm, rash, and urticaria. Discontinue immediately (and permanently) in patients who experience serious allergic/anaphylactic reactions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pure red cell aplasia (PRCA): Cases of severe anemia and PRCA (with or without other cytopenias) have been reported, predominantly in patients with chronic kidney disease receiving SubQ darbepoetin alfa (the intravenous [IV] route is preferred for hemodialysis patients). Cases have also been reported in patients with hepatitis C who were receiving ESAs, interferon, and ribavirin. Patients with a sudden loss of response to darbepoetin alfa (with severe anemia and a low reticulocyte count) should be evaluated for PRCA with associated neutralizing antibodies to erythropoietin; discontinue treatment (permanently) in patients with PRCA secondary to neutralizing antibodies to erythropoietin. Antibodies may cross-react; do not switch to another ESA in patients who develop antibody-mediated anemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cancer patients: <b>[US Boxed Warning]: A shortened overall survival and/or increased risk of time to tumor progression or recurrence has been reported in studies with breast, cervical, head and neck, lymphoid, and non-small cell lung cancer patients.</b> It is of note that in most of these studies, patients received ESAs to a target hemoglobin of &ge;12 g/dL; although risk has not been excluded when dosed to achieve a target hemoglobin of &lt;12 g/dL. <b>[US Boxed Warnings]: To decrease these risks, and risk of cardio- and thrombovascular events, use the lowest dose needed to avoid red blood cell transfusions. Use ESAs in cancer patients only for the treatment of anemia related to concurrent myelosuppressive chemotherapy; discontinue ESA following completion of the chemotherapy course. ESAs are <span style=\"text-decoration: underline\">not</span> indicated for patients receiving myelosuppressive therapy when the anticipated outcome is curative.</b> A dosage modification is appropriate if hemoglobin levels rise &gt;1 g/dL per 2-week time period during treatment (Rizzo 2010). Use of ESAs has been associated with an increased risk of venous thromboembolism (VTE) without a reduction in transfusions in patients &gt;65 years of age with cancer (Hershman 2009). Improved anemia symptoms, quality of life, fatigue, or well-being have not been demonstrated in controlled clinical trials.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chronic kidney disease patients: <b>[US Boxed Warning]: An increased risk of death, serious cardiovascular events, and stroke was reported in chronic kidney disease patients administered ESAs to target hemoglobin levels &gt;11 g/dL; use the lowest dose sufficient to reduce the need for RBC transfusions. An optimal target hemoglobin level, dose, or dosing strategy to reduce these risks has not been identified in clinical trials. </b> Hemoglobin rising &gt;1 g/dL in a 2-week period may contribute to the risk (dosage reduction recommended). Chronic kidney disease patients who exhibit an inadequate hemoglobin response to ESA therapy may be at a higher risk for cardiovascular events and mortality compared to other patients. ESA therapy may reduce dialysis efficacy (due to increase in red blood cells and decrease in plasma volume); adjustments in dialysis parameters may be needed. Chronic kidney disease patients not requiring dialysis may have a better response to darbepoetin alfa and may require lower doses. Patients treated with ESAs may require increased heparinization during dialysis to prevent clotting of the extracorporeal circuit.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypertension: Use with caution in patients with a history of hypertension; use is contraindicated in patients with uncontrolled hypertension. An excessive rate of rise of hemoglobin may be associated with exacerbation of hypertension; decrease the darbepoetin alfa dose if the hemoglobin increase exceeds 1 g/dL in any 2-week period. Blood pressure should be controlled prior to start of therapy and monitored closely throughout treatment. Hypertensive encephalopathy has been reported with patients receiving erythropoietic therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Perisurgical patients: Increased mortality was observed in patients undergoing coronary artery bypass surgery who received epoetin; these deaths were associated with thrombotic events. An increased risk of deep vein thrombosis has been observed in patients treated with epoetin undergoing surgical orthopedic procedures. Darbepoetin alfa is <b>not</b> approved for reduction in allogeneic red blood cell transfusions in patients scheduled for surgical procedures.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: The risk for seizures is increased with darbepoetin alfa use in patients with chronic kidney disease; use with caution in patients with a history of seizures. Monitor closely for neurologic symptoms during the first several months of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Severe anemia or acute blood loss: Due to the delayed onset of erythropoiesis, darbepoetin alfa is not recommended for acute correction of severe anemia or as a substitute for emergency transfusion.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Latex: The packaging of some formulations may contain latex.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Oncology: The American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH) 2010 updates to the clinical practice guidelines for the use of ESAs in patients with cancer indicate that ESAs are appropriate when used according to the parameters identified within the FDA-approved labeling for epoetin and darbepoetin alfa (Rizzo 2010). ESAs are an option for chemotherapy-associated anemia when the hemoglobin has fallen to &lt;10 g/dL to decrease the need for red blood cell transfusions. ESAs should only be used in conjunction with concurrent chemotherapy. Although the FDA label now limits ESA use to the palliative setting, the ASCO/ASH guidelines suggest using clinical judgment in weighing risks versus benefits as formal outcomes studies of ESA use defined by intent of chemotherapy treatment have not been conducted.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">- Cardiovascular disease: The American College of Physicians recommends against the use of ESAs in patients with mild to moderate anemia and heart failure or coronary heart disease (ACP [Qaseem 2013]). The American College of Cardiology Foundation/American Heart Association (ACCF/AHA) 2013 Heart Failure Guidelines do not provide a clear recommendation on the use of ESAs in anemic heart failure patients. The effects of ESAs on quality of life measures, morbidity, and mortality are potentially modest and still unclear. The authors declined to provide an official recommendation regarding the use of ESAs pending the completion of ongoing randomized trials (ACCF/AHA [Yancy 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Factors impairing erythropoiesis: Prior to treatment, correct or exclude deficiencies of iron, vitamin B<sub>12</sub>, and/or folate, as well as other factors that may impair erythropoiesis (inflammatory conditions, infections, bleeding). Poor response to therapy should prompt evaluation of potential factors impairing erythropoiesis, as well as possible malignant processes and hematologic disease (thalassemia, refractory anemia, myelodysplastic disorder), occult blood loss, hemolysis, osteitis fibrosa cystic, and/or bone marrow fibrosis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299127\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156955\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13206&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Lenalidomide: Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Lenalidomide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nandrolone: May enhance the stimulatory effect of Erythropoiesis-Stimulating Agents. Specifically, nandrolone may enhance the erythropoiesis stimulatory effect of Erythropoiesis-Stimulating Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pomalidomide: Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Pomalidomide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thalidomide: Erythropoiesis-Stimulating Agents may enhance the thrombogenic effect of Thalidomide. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156957\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156969\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Women who become pregnant during treatment with darbepoetin alfa are encouraged to enroll in Amgen&rsquo;s Pregnancy Surveillance Program (800-772-6436).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1057680\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Hemoglobin (at least once per week until maintenance dose established and after dosage changes; monitor less frequently once hemoglobin is stabilized); CKD patients should be also be monitored at least monthly following hemoglobin stability; iron stores (transferrin saturation and ferritin) prior to and during therapy; serum chemistry (CKD patients); blood pressure; fluid balance (CKD patients); monitor for signs of seizures (CKD patients following initiation for first few months, includes new-onset or change in seizure frequency or premonitory symptoms)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Cancer patients: Examinations recommended by the ASCO/ASH guidelines (Rizzo 2010) prior to treatment include peripheral blood smear (in some situations a bone marrow exam may be necessary), assessment for iron, folate, or vitamin B<sub>12</sub> deficiency, reticulocyte count, renal function status, and occult blood loss; during ESA treatment, assess baseline and periodic iron, total iron-binding capacity, and transferrin saturation or ferritin concentrations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156950\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Darbepoetin alfa induces erythropoiesis by stimulating the division and differentiation of committed erythroid progenitor cells; induces the release of reticulocytes from the bone marrow into the bloodstream, where they mature to erythrocytes. There is a dose-response relationship with this effect. This results in an increase in reticulocyte counts followed by a rise in hematocrit and hemoglobin levels. When administered SubQ or IV, darbepoetin alfa's half-life is ~3 times that of epoetin alfa concentrations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156965\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Increased hemoglobin levels not generally observed until 2 to 6 weeks after initiating treatment</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: SubQ: Slow</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents: Initial dose: 51.6 &plusmn; 13.7 mL/kg; Steady state: 80.9 &plusmn; 32.5 mL/kg (Lerner 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: 52.4 &plusmn; 2 mL/kg (Macdougall 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability: CKD: SubQ: Adults: ~37% (range: 30% to 50%); Children: 54% (range: 32% to 70%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination: <b>Note:</b> Darbepoetin alfa half-life is approximately 3-fold longer than epoetin alfa following IV administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CKD:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents (Lerner 2002):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: Terminal: 22.1 &plusmn; 4.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">SubQ: Terminal: 42.8 &plusmn; 23 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV: 21 hours</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">SubQ: Nondialysis patients: 70 hours (range: 35 to 139 hours), Dialysis patients: 46 hours (range: 12 to 89 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cancer:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents: SubQ: 49.4 &plusmn; 32 hours (Blumer 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: SubQ: 74 hours (range: 24 to 144 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak: SubQ:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CKD:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents: 36.2 &plusmn; 14.1 hours (Lerner 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: 48 hours (range: 12 to 72 hours; independent of dialysis)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cancer:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children and Adolescents: 87.5 &plusmn; 53 hours (Blumer 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adults: 71 hours (range: 28 to 123 hours)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F156968\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Aranesp (Albumin Free) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mcg/mL (1 mL): $232.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mcg/mL (1 mL): $371.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mcg/mL (1 mL): $557.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/mL (1 mL): $928.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg/mL (1 mL): $1,857.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mcg/mL (1 mL): $2,786.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Aranesp (Albumin Free) Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mcg/0.4 mL (0.4 mL): $92.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mcg/0.42 mL (0.42 mL): $232.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mcg/0.4 mL (0.4 mL): $371.52</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mcg/0.3 ml (0.3 mL): $557.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mcg/0.5 mL (0.5 mL): $928.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">150 mcg/0.3 ml (0.3 mL): $1,393.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">200 mcg/0.4 mL (0.4 mL): $1,857.60</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">300 mcg/0.6 mL (0.6 mL): $2,786.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 mcg/mL (1 mL): $4,644.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038595\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Actorise (IN);</li>\n      <li>Aranesp (AE, AT, AU, BB, BE, BG, BH, CH, CR, CY, CZ, DE, DK, DO, EE, ES, FI, FR, GB, GR, GT, HN, HR, IE, IL, IS, IT, JO, KW, LB, LT, LU, LV, MT, NI, NL, NO, NZ, PA, PL, PT, QA, RO, SA, SE, SI, SK, SV, TR, TW, UA);</li>\n      <li>NESP (HK, JP, KR, MY, PH, SG, TH, TW);</li>\n      <li>Nespo (SE)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A. Polysorbate 80 and E-Ferol toxicity. Pediatrics. 1986;77(4):593-597.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aranesp (darbepoetin alfa) [prescribing information]. Thousand Oaks, CA: Amgen Inc; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Blumer J, Berg S, Adamson PC, et al, &quot;Pharmacokinetic Evaluation of Darbepoetin Alfa for the Treatment of Pediatric Patients With Chemotherapy-Induced Anemia,&quot; <i>Pediatr Blood Cancer</i>, 2007, 49(5):687-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-pediatric-drug-information/abstract-text/17120240/pubmed\" target=\"_blank\" id=\"17120240\">17120240</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. MMWR Morb Mortal Wkly Rep. 1984;33(14):198-199<a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm\" target=\"_blank\"> http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cohen V, Jellinek SP, Teperikidis L, et al. Room-temperature storage of medications labeled for refrigeration. <i>Am J Health-Syst Pharm</i>. 2007;64(16):1711-1715.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-pediatric-drug-information/abstract-text/17687059/pubmed\" target=\"_blank\" id=\"17687059\">17687059</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hershman DL, Buono DL, Malin J, McBride R, Tsai WY, Neugut AI. Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. <i>J Natl Cancer Inst</i>. 2009;101(23):1-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-pediatric-drug-information/abstract-text/19903808/pubmed\" target=\"_blank\" id=\"19903808\">19903808</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. Contact Dermatitis. 2002;47:313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lerner G, Kale AS, Warady BA, et al, &ldquo;Pharmacokinetics of Darbepoetin Alfa in Pediatric Patients With Chronic Kidney Disease,&rdquo; <i>Pediatr Nephrol</i>, 2002, 17(11):933-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-pediatric-drug-information/abstract-text/12432437/pubmed\" target=\"_blank\" id=\"12432437\">12432437</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. Contact Dermatitis. 2000;43:172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Macdougall IC, Gray SJ, Elston O, Breen C, Jenkins B, Browne J, Egrie J. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. <i>J Am Soc Nephrol</i>. 1999;10(11):2392-2395.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-pediatric-drug-information/abstract-text/10541299/pubmed\" target=\"_blank\" id=\"10541299\">10541299</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Qaseem A, Humphrey LL, Fitterman N, Starkey M, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Treatment of anemia in patients with heart disease: a clinical practice guideline from the american college of physicians. <i>Ann Intern Med</i>. 2013;159(11):770-779.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-pediatric-drug-information/abstract-text/24297193/pubmed\" target=\"_blank\" id=\"24297193\">24297193</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rizzo JD, Brouwers M, Hurley P, et al, &quot;American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update on the Use of Epoetin and Darbepoetin in Adult Patients With Cancer,&quot; <i>J Clin Oncol</i>, 2010, 28(33):4996-5010.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-pediatric-drug-information/abstract-text/20975064/pubmed\" target=\"_blank\" id=\"20975064\">20975064</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rizzo JD, Somerfield MR, Hagerty KL, et al, &quot;Use of Epoetin and Darbepoetin in Patients With Cancer: 2007 American Society of Hematology/American Society of Clinical Oncology Clinical Practice Guideline Update,&quot; <i>Blood</i>, 2008, 111(1):25-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-pediatric-drug-information/abstract-text/17954703/pubmed\" target=\"_blank\" id=\"17954703\">17954703</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. Lancet. 1995;345(8980):1312-1313.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. <i>Circulation</i>. 2013;128(16):e240-e327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/darbepoetin-alfa-pediatric-drug-information/abstract-text/23741058/pubmed\" target=\"_blank\" id=\"23741058\">23741058</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13206 Version 122.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F50080059\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708695\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F156983\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F156984\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1057681\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1057675\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F156961\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F156947\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874543\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1057684\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F156979\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1057683\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2136826\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F157016\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F156966\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F156951\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299127\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F156955\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F156957\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F156969\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1057680\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F156950\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F156965\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F156968\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038595\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13206|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=darbepoetin-alfa-drug-information\" class=\"drug drug_general\">Darbepoetin alfa: Drug information</a></li><li><a href=\"topic.htm?path=darbepoetin-alfa-patient-drug-information\" class=\"drug drug_patient\">Darbepoetin alfa: Patient drug information</a></li></ul></div></div>","javascript":null}